Havrix Junior Monodose

Havrix Junior Monodose is a monodose injectable suspension that contains inactivated hepatitis A virus and aluminium hydroxide as an adjuvant. It is supplied as a single-dose vial for intramuscular administration and is marketed in the European Union. The vaccine belongs to the hepatitis A vaccine class and is prescribed to induce active immunity against hepatitis A infection in children and travelers to endemic areas globally.

Havrix Junior Monodose is indicated for specific preventive purposes related to hepatitis A.

- Primary prophylaxis of hepatitis A in children according to national immunization schedules. - Pre‑exposure vaccination for travelers visiting regions with intermediate or high hepatitis A endemicity. - Use in outbreak settings to quickly immunize susceptible pediatric populations. - Administration as part of a two‑dose series, with the second dose typically given 6–12 months after the first.

The safety profile of Havrix Junior Monodose reflects the typical reactions observed with inactivated viral vaccines.

Common: - Mild pain, redness or swelling at the injection site. - Low‑grade fever. - Headache. - Fatigue or general malaise. - Nausea.

Serious: - Severe allergic reaction (anaphylaxis) characterized by difficulty breathing, swelling of the face or throat, and rapid pulse. - Guillain‑Barré syndrome, a rare neurological condition. - Persistent high fever lasting more than 48 hours. - Seizures (rare). - Thrombocytopenia (low platelet count).

Healthcare providers should consider several precautionary measures before administering Havrix Junior Monodose.

- Confirm no history of severe allergic reaction to any component of the vaccine, especially aluminium salts. - Defer vaccination in individuals with acute moderate or severe illness until recovery. - Use with caution in persons with known immunodeficiency, as response may be reduced. - Discuss potential benefits versus risks in pregnant or breastfeeding women, as safety data are limited. - Observe the patient for at least 15 minutes after injection to monitor for immediate reactions. - Record any previous hepatitis A vaccination to avoid unnecessary repeat dosing.

Havrix Junior Monodose may interact with other agents, influencing its efficacy or safety.

Avoid: - Simultaneous administration with live viral vaccines (e.g., measles, mumps, rubella) unless separated by at least 4 weeks. - Use with immunoglobulin products that contain hepatitis A antibodies, which can neutralize the vaccine antigen.

Use with caution: - Concomitant administration of other inactivated vaccines (e.g., diphtheria‑tetanus‑pertussis) may increase local reactogenicity. - Patients receiving immunosuppressive therapy may have a diminished antibody response. - Antipyretics taken prophylactically may mask mild fever after vaccination.